Navigating Share Purchase Agreements versus Asset Purchase Agreements in the HealthTech and MedTech Ecosystems

Nelson Advisors
7 minutes ago
15 min read

Comparative Strategic Framework: Navigating Share Purchase Agreements versus Asset Purchase Agreements in the HealthTech and MedTech Ecosystems

The structural determination of a transaction in the HealthTech and MedTech sectors, specifically the choice between a Share Purchase Agreement (SPA) and an Asset Purchase Agreement (APA), constitutes the most significant strategic pivot point for investors, founders and legal counsel.

In an industry where valuation is predicated on a complex interplay of regulatory milestones, intellectual property (IP) robustness and high-fidelity patient data, the legal mechanism of transfer serves as the primary arbiter of post-closing operational risk and commercial viability.

This report provides an analysis of these two instruments, detailing their divergent implications for regulatory compliance, data sovereignty, liability allocation and tax efficiency within the specific context of the United Kingdom’s legal and clinical landscape.

Structural Paradigms and the Nature of Transfer

The fundamental distinction between an SPA and an APA lies in the legal object being transferred. In a Share Purchase Agreement, the transaction occurs at the shareholder level; the buyer acquires the equity of the target company, which remains a distinct legal entity throughout the process.

Consequently, the company continues to own all its assets, hold all its contracts, and critically remain responsible for all its historic liabilities. This structure provides a "business as usual" continuity that is often favoured in complex regulated sectors where the cost of disrupting licenses or contracts is prohibitive.

Conversely, an Asset Purchase Agreement involves the targeted acquisition of specific business components. The buyer "cherry-picks" desirable assets, such as a proprietary diagnostic algorithm, a patent portfolio, or a specific medical device product line, while the legal entity (and its associated corporate history) remains with the seller.

While this provides the buyer with a clean slate by leaving behind unwanted liabilities, it necessitates a granular and often labor-intensive process of individual asset identification and legal assignment.

Transactional Aspect	Share Purchase Agreement (SPA)	Asset Purchase Agreement (APA)
Primary Object	Company shares/equity	Specific assets (tangible/intangible)
Legal Personality	Target entity remains unchanged	Buyer entity (NewCo) acquires assets
Liability Retention	Buyer inherits all "warts and all"	Seller retains legacy liabilities (mostly)
Operational Impact	High continuity; minimal disruption	High disruption; requires new setup
Contractual Rights	Transferred via ownership change	Require individual assignment/novation
Third-Party Consents	Limited (unless change of control)	Extensive (mandatory for most assets)

Regulatory Continuity and MHRA Compliance Frameworks

In the MedTech and HealthTech sectors, the "right to market" is the definitive asset. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees a rigorous framework for both medicinal products and medical devices. The choice of deal structure dictates whether the transition of these rights is a seamless administrative update or a major regulatory hurdle.

The SPA Advantage: Maintaining the Legal Manufacturer Status

Under an SPA, the legal entity that is registered as the "manufacturer" or "Marketing Authorisation Holder" (MAH) does not change. Because the company remains the same, registrations with the MHRA and existing UK Responsible Person (UKRP) designations persist without the need for a formal transfer of ownership.

This is particularly vital in the current post-Brexit environment, where the UK is transitioning away from EU CE-marking toward the UKCA (UK Conformity Assessed) mark. Existing CE-marked general medical devices can remain on the Great Britain market until June 2028 or 2030, provided the manufacturer remains compliant with EU directives.

An SPA allows a buyer to leverage these lengthy transitional periods without triggering the re-registration requirements that would accompany a change in the manufacturer's corporate identity.

The APA Challenge: Transfer of Marketing Authorisations and DORS Updates

In an asset deal, the buyer is a different legal entity, which triggers a mandatory "Change of Ownership" (CoA) process for any Marketing Authorisations (MAs) involved. This process is far from clerical. The transferee must obtain a new product-licence (PL) number and submit a comprehensive application via the MHRA portal or the Central European Systems Platform (CESP) in eCTD format.

The administrative burden of an APA in MedTech includes:

Mandatory Labeling Changes: Every product, instruction for use (IFU), and packaging unit must be updated to reflect the new legal entity's name and address. This can necessitate a total recall and re-labelling of existing stock if the transitional "sell-through" periods are not negotiated.
MHRA DORS Updates: For medical devices, the new owner must register with the Device Online Registration System (DORS). If the seller was based outside the UK and used a UKRP, the buyer must appoint their own UKRP or act as the manufacturer if they have a UK base.
Timelines and Delays: While the MHRA aims to process MAs within 30 to 42 days, the process for medical device registration changes can be unpredictable, especially if the MHRA issues a Validation Correction Request (VCR), which requires a response within 10 working days.

Regulatory Requirement	SPA (Share Sale)	APA (Asset Sale)
Manufacturer Identity	No change	Changes to the buyer entity
MHRA Registration	Remains valid/update account details	Full new registration/transfer required
Product-Licence (PL) No.	Retained	New number usually required
Packaging/Labelling	No change required	Must reflect new owner details
UK Responsible Person	Contract remains with entity	New appointment/contract needed

Intellectual Property and Intangible Asset Chains

The valuation of HealthTech firms is frequently concentrated in intangible assets: proprietary software code, artificial intelligence (AI) models, patents and trade secrets. The mechanism for securing these assets differs fundamentally between the two agreement types.

Automaticity and Continuity in SPAs

In an SPA, the target company continues to own its intellectual property. There is no "transfer" of the IP itself, only a transfer of the ownership of the entity that holds the IP. This provides a high degree of security, as the chain of title remains unbroken. Built-in continuity ensures that existing license agreements, development contracts, and collaborations with academic institutions remain in force.

However, legal counsel must meticulously review "change of control" clauses. In the HealthTech sector, many technology licenses from universities or research organisations include provisions that allow the licensor to terminate the agreement or renegotiate terms if the company is acquired.

The Precision of APA Assignments

In an APA, IP does not transfer by default; it must be explicitly identified, valued, and assigned. Under Section 90(3) of the Copyright, Designs and Patents Act 1988, an assignment of copyright is not effective unless it is in writing and signed by the assignor.

For a MedTech buyer, this means executing specific assignment deeds for:

Patents and Trademarks: These must be recorded with the UK Intellectual Property Office (UKIPO) to be enforceable against third parties. Failure to record a transfer within six months can limit the buyer's ability to claim damages for infringement occurring before the registration.
Software and AI Algorithms: Given the collaborative nature of coding, the buyer must ensure that all developers—whether employees or contractors, have signed valid IP assignments to the seller before those rights are transferred to the buyer.
Confidential Information: While trade secrets are not "property" in the same sense as patents, they are transferred via the physical or digital delivery of data rooms and the execution of stringent non-disclosure and non-compete agreements.

IP Asset Class	SPA Transfer Mechanism	APA Transfer Mechanism	Legal Requirement
Registered Patents	Continuity of corporate ownership	Deed of Assignment + UKIPO update	Patents Act 1977
Software Copyright	Continuity of corporate ownership	Written Assignment signed by assignor	CDPA 1988
Trademarks	Continuity of corporate ownership	Assignment + UKIPO recordal	Trade Marks Act 1994
Unregistered Design	Continuity of corporate ownership	Written Assignment	CDPA 1988
Confidential Info	Continuity of corporate ownership	Contractual delivery + NDAs	Common Law

Data Privacy, Patient Data and the UK GDPR

HealthTech transactions are unique in their reliance on "special category" personal data. Health information, genetic data, and biometric identifiers are subject to the highest level of protection under the UK GDPR and the Data Protection Act 2018.

Data Controller Stability in SPAs

The primary advantage of the SPA structure is that the "Data Controller", the legal entity responsible for the data, does not change. Only the ownership of the controller changes. Because the entity processing the patient data remains the same, there is no "sharing" or "transfer" of data between distinct legal personalities in a way that would trigger a need for a new legal basis under Article 6 or Article 9 of the GDPR.

The continuity of the data controller significantly reduces the risk of privacy related litigation and avoids the logistical nightmare of notifying thousands of patients of a change in data ownership.

The Regulatory Gauntlet of APA Data Transfers

In an APA, the data is being transferred from the seller entity to a different legal entity (the buyer). This constitutes a "transfer" under GDPR, requiring a lawful basis for both the disclosure by the seller and the acquisition by the buyer.

Legitimate Interest vs. Consent: For regular personal data (e.g., business contact details), the "legitimate interest" basis (Article 6(1)(f)) may suffice, provided a Legitimate Interest Assessment (LIA) is performed. However, for special category health data, the threshold is much higher. European and UK data protection authorities (such as the DSK in Germany and the ICO in the UK) suggest that there is "no room" for transferring health data in an asset deal without the explicit consent of the individuals concerned.
The "Two-Cabinet Solution": To comply with data protection principles like data minimization, buyers and sellers in an APA often utilize a "two-cabinet" approach. Active patient data is transferred (subject to consent/LIA), while historic data that must be kept for statutory retention periods is held by the buyer as a "data processor" for the seller, ensuring that the buyer does not become the controller of data they do not need for the ongoing business.
Due Diligence Phase: Even before the deal closes, the sharing of data in the data room must be justified. Usually, this is based on legitimate interest for the purpose of the transaction, but sensitive health data should be anonymised or pseudonymised to the greatest extent possible during the DD phase.

Data Category	SPA Transaction	APA Transaction	GDPR Requirement
Employee Data	No change in employer	Automatic transfer (TUPE)	Art 6(1)(b) / (f)
Patient Health Data	Continuity of controller	Requires explicit consent usually	Art 9(2)(a)
Marketing Lists	Continuity of controller	Requires new consent/opt-out	PECR / Art 6(1)(a)
Financial Records	Continuity of controller	Retained for statutory periods	Art 6(1)(c)

Liability Allocation, Clinical Trials and Product Safety

In the MedTech sector, liabilities are often "long-tail," meaning claims for defective products or clinical trial injuries can arise years after the initial incident. The choice of agreement structure serves as the primary mechanism for allocating this risk.

Inherited Risk in Share Deals

In an SPA, the buyer acquires the company "warts and all". This includes all historic liabilities under the Consumer Protection Act 1987 (CPA), which imposes strict liability for defective products that cause personal injury or property damage.

If a MedTech firm manufactured a defective implant three years ago, the buyer who acquires the shares today will inherit the legal and financial responsibility for any subsequent claims.

To mitigate this, SPAs in the HealthTech sector feature extensive "Warranties and Indemnities" (W&I). Sellers are often required to provide specific indemnities for:

Known litigation or regulatory investigations.
Tax liabilities relating to pre-completion periods.
Environmental or product safety non-compliance.

Risk Shielding in Asset Deals

The fundamental appeal of the APA is the ability to leave legacy liabilities behind. The buyer only assumes the liabilities that are explicitly "assumed" in the contract. If the buyer is acquiring only a specific diagnostic software line from a larger company, they can ensure they are not responsible for the seller's unrelated debts or litigation.

However, "successor liability" remains a risk. Under the CPA, an entity that "puts its name" on a product or uses a trademark in relation to it can be held liable. If a buyer continues to market a product under the same brand name as the seller, they may find themselves pulled into litigation, even if the defect originated before the transfer.

Clinical Trial Governance

Clinical Trial Agreements (CTAs) present unique challenges in M&A.

In an SPA: The target company remains the "Sponsor." Existing CTAs with NHS Trusts remain valid, and clinical trial insurance policies continue to cover the entity (subject to insurer notification).
In an APA: The "Sponsorship" must be transferred. This involves novating the CTAs with every participating hospital and university trust. This requires approval from the Health Research Authority (HRA) and potentially the four nations contracting leads group if modifications to model agreements are required. The buyer must also demonstrate they have appropriate "Clinical Trials Liability" insurance to cover negligent and non-negligent harm to subjects.

Risk Category	SPA Liability Profile	APA Liability Profile	Mitigation Strategy
Product Defect	Inherited by Buyer	Stays with Seller	W&I Insurance / Indemnities
Clinical Trial Injury	Inherited by Buyer	Stays with Seller (pre-transfer)	New insurance / Novation
Malpractice	Inherited by Buyer	Stays with Seller	Professional Indemnity
Regulatory Fines	Inherited by Buyer	Stays with Seller	Compliance DD

Employment and the TUPE Shield

In HealthTech, the "product" is often inseparable from the people who built it. The Transfer of Undertakings (Protection of Employment) Regulations (TUPE) provide a protective framework for these employees.

In a Share Purchase Agreement, TUPE is generally not triggered because there is no change in the legal employer. only the shareholder changes.

The employees' contracts, seniority, and benefits continue uninterrupted. This provides a clean transition and avoids the complex information and consultation requirements that can distract from the core business during a merger

In an Asset Purchase Agreement, if the assets being transferred constitute a "stable economic entity," TUPE applies automatically. This has several critical implications:

Automatic Transfer: All employees "assigned" to the business or part of the business being sold transfer to the buyer on their existing terms and conditions.
Protection Against Dismissal: Any dismissal where the "sole or principal reason" is the transfer is automatically unfair, unless there is an "Economic, Technical, or Organisational" (ETO) reason entailing changes in the workforce.
Duty to Inform and Consult: Both the buyer and seller must inform and consult with recognized trade unions or elected employee representatives. Failure to do so can result in a tribunal award of up to 13 weeks' uncapped pay per affected employee.
Liability Transfer: All the seller's rights, powers, duties, and liabilities under the employment contracts (including outstanding salary, holiday pay, and even potential discrimination claims) transfer to the buyer.

Taxation and Financial Incentives

The choice of deal structure is often a zero-sum game regarding tax efficiency.

Seller Considerations: The SPA and BADR

Sellers overwhelmingly prefer SPAs because they receive the sale proceeds directly. In the UK, individual shareholders may qualify for Business Asset Disposal Relief (formerly Entrepreneurs' Relief), which can reduce the Capital Gains Tax (CGT) rate from 20% to 10% on the first £1 Million of lifetime gains. Corporate sellers may benefit from the Substantial Shareholding Exemption (SSE), allowing them to receive proceeds free of Corporation Tax.

In an APA, the seller is the company, not the shareholders. The company pays 25% Corporation Tax on any gain from the sale of assets, and the shareholders are then taxed again when the remaining cash is distributed as a dividend or on liquidation.

Buyer Considerations: APAs and Capital Allowances

Buyers often prefer APAs because they can "re-base" the value of the assets. In an asset purchase, the buyer can often claim capital allowances on the purchase price of plant and machinery (including hardware) and relief for the cost of acquiring intangible assets.

In an SPA, the buyer inherits the target's historic tax basis, which may offer significantly less relief. However, an SPA allows the buyer to inherit the target's "trading losses," which can be used to offset future profits of the acquired company (subject to "loss-streaming" and "change of ownership" rules).

R&D Tax Credits in Transition

For loss-making HealthTech startups, R&D tax credits are a vital source of non-dilutive funding.

In an SPA: The company’s eligibility for R&D tax credits continues. The history of R&D expenditure remains with the entity, allowing for continued claims under the merged Research and Development Expenditure Credit (RDEC) scheme or the Enhanced R&D Intensive Support (ERIS) for R&D-intensive SMEs.
In an APA: R&D tax credits do not "transfer" as an asset. The buyer can only claim for expenditure they personally incur after the closing date. The historic credits (and any pending claims) remain with the seller company.

Tax Item	Share Purchase (SPA)	Asset Purchase (APA)
Stamp Duty	0.5% (Stamp Duty Reserve Tax)	SDLT on property; 0% on most IP/Goodwill
Seller Tax	CGT (10-20%)	Corporation Tax (25%) + Distribution Tax
Buyer Capital Allowances	Restricted to historic cost	Available on current purchase price
VAT Treatment	Exempt	Transfer of Going Concern (TOGC) = 0%
Tax Losses	Inherited (subject to restrictions)	Stay with Seller

Due Diligence: Depth vs. Breadth

The scope of due diligence (DD) is fundamentally different for each structure. In an SPA, because the buyer is inheriting the entire corporate history, the DD must be exhaustive. This includes reviewing:

Corporate Governance: Ensuring all shares were properly issued and that there are no "untraceable" shareholders who could block the deal.
Historical Tax Compliance: Looking for "undisclosed tax debts" that would become the buyer's problem post-completion.
Employment History: Reviewing pension liabilities and historical compliance with working time regulations.

In an APA, DD is more focused on "asset quality" and "chain of title." The buyer spends less time on the seller's corporate minutes and more time on:

Freedom to Operate (FTO): Ensuring the technology being acquired does not infringe third-party patents.
Contractual Assignability: Reviewing every customer and supplier contract to see if it can be assigned without the third party’s consent, a major bottleneck in asset deals.
Device History Records: Ensuring the technical documentation required by the MHRA for medical devices is complete and ready for transfer.

Operational Integration and the "Dead Period" Risk

A critical, and often overlooked, difference between the two structures is the risk of a "dead period" in sales during the integration phase.

In an SPA, the transition is theoretically instantaneous. On the day of completion, the buyer owns the company, and the company continues to sell its products under its existing licenses and labels.

In an APA, there is a logistical "lag." The buyer cannot legally place a medical device on the market until they are registered as the manufacturer with the MHRA and the product labeling reflects their details. If the MHRA transfer process takes 42 days, and the buyer has not pre-printed labels, they may face a six-week period where they cannot fulfill orders.

To mitigate this, APA transition services agreements (TSAs) often include provisions where the seller continues to act as the "nominal manufacturer" for a period while the buyer completes their registrations.

Strategic Decision Making: Startup v's Mature Firm

The preference for SPA or APA often correlates with the maturity of the HealthTech firm.

Pre-Revenue Startups and Research Spin-outs

For very early-stage startups, an APA may be the only viable structure. If the startup has a "messy" cap table or unresolved disputes among founders, a buyer may insist on an APA to acquire the core technology while avoiding the corporate drama. However, for the founders, this is often a tax disaster, leading them to push for an SPA whenever possible.

Established MedTech and Mid-Market Firms

For mature firms with established products, the SPA is the standard. The complexity of transferring thousands of MHRA registrations, novating hundreds of NHS hospital contracts, and navigating the TUPE requirements for a large workforce makes an APA prohibitively expensive and risky. In these cases, the "clean break" offered by an APA is overshadowed by the "operational paralysis" it can cause.

Strategic Conclusions and Recommendations

The choice between an SPA and an APA in the HealthTech and MedTech sectors is not a mere legal technicality; it is a fundamental business decision that dictates the trajectory of the acquisition.

The Share Purchase Agreement remains the "gold standard" for enterprise acquisitions where operational continuity is the primary objective. By preserving the legal identity of the target, the SPA maintains the integrity of the "regulatory ecosystem", existing MHRA registrations, patient data controller status and employment relationships remain undisturbed. While the buyer assumes greater risk via historic liabilities, this is typically managed through rigorous due diligence and robust W&I insurance.

The Asset Purchase Agreement is a specialised tool best suited for distressed acquisitions, carve-outs of specific product lines, or high-risk startups where the buyer must insulate themselves from legacy litigation.

However, the APA "tax" is paid in administrative complexity. The requirement to manually re-establish regulatory standing, secure patient consent for data transfers, and novate clinical trial agreements can create significant friction and delay commercialisation.

For professional peers navigating these transactions, the following insights should govern the structural choice:

Regulatory Priority: If the asset is a medicinal product with a valid Marketing Authorisation, the 30-42 day MHRA transfer timeline in an APA must be factored into the closing schedule.
Data as Asset: In deals where the value is in the database (e.g., diagnostic AI), an SPA is nearly mandatory to avoid the "consent requirement" for special category data under GDPR.
IP Chain of Title: In an APA, the "written and signed" requirement of Section 90 CDPA 1988 is a non-negotiable hurdle for software copyright.
Human Capital: If the deal relies on retaining key scientific talent, the automaticity of an SPA is superior to the mandatory consultation and potential disruption of a TUPE transfer in an APA.

In the final analysis, the HealthTech transaction is a balancing act between the desire for a "clean slate" and the necessity of "commercial momentum." The most successful deals are those where the legal structure is chosen not for its simplicity, but for its ability to protect the delicate clinical and regulatory foundations upon which HealthTech value is built.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech